Altimmune, Inc. (ALT) Return on equity 2016–2025
Altimmune, Inc. (ALT) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-39.2%FY2025 · since FY2016: -34.4% → -39.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -39.2% | +37.8 pp |
| FY2024 | -77.0% | -31.4 pp |
| FY2023 | -45.6% | +0.2 pp |
| FY2022 | -45.7% | +3.0 pp |
| FY2021 | -48.8% | -27.0 pp |
| FY2020 | -21.7% | +23.4 pp |
| FY2019 | -45.1% | +36.0 pp |
| FY2018 | -81.1% | +36.8 pp |
| FY2017 | -117.8% | -83.4 pp |
| FY2016 | -34.4% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice